Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Monoclonal TNFSF13 Primary Antibody for FACS, ICC - ABIN4281286
Pelekanou, Kampa, Kafousi, Darivianaki, Sanidas, Tsiftsis, Stathopoulos, Tsapis, Castanas: Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. in BMC cancer 2008
Show all 2 Pubmed References
Human Polyclonal TNFSF13 Primary Antibody for CyTOF, FACS - ABIN4900679
Moreaux, Legouffe, Jourdan, Quittet, Rème, Lugagne, Moine, Rossi, Klein, Tarte: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. in Blood 2004
Show all 2 Pubmed References
Human Monoclonal TNFSF13 Primary Antibody for ELISA, WB - ABIN563762
Guadagnoli, Kimberley, Phan, Cameron, Vink, Rodermond, Eldering, Kater, van Eenennaam, Medema: Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. in Blood 2011
Human Monoclonal TNFSF13 Primary Antibody for ELISA - ABIN2479512
Yadava, Dutta: Lethal action of bile on axenically grown E. histolytica and the influence of bile salts on the amoebicidal activity of emetine and metronidazole. in The Indian journal of medical research 1976
Show all 2 Pubmed References
Mouse (Murine) Monoclonal TNFSF13 Primary Antibody for ELISA, Func - ABIN1169000
Matthes, Dunand-Sauthier, Santiago-Raber, Krause, Donze, Passweg, McKee, Huard: Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. in Blood 2011
TNFSF13, SPATC1L, SLC22A25 (show SLC22A25 Antibodies) and SALL4 (show SALL4 Antibodies) may thus be novel susceptibility loci for atrial fibrillation in the Japanese population
The results suggest that increased levels of BAFF (show TNFSF13B Antibodies) and APRIL produced in the central nervous system may influence the development of anti-neutrophil cytoplasmic antibody-hypertrophic pachymeningitis.
The genetic variations and gene expression level of TNFSF13 are associated with the susceptibility and severity of IgA nephropathy in a Han Chinese population.
APRIL but not BLyS (show TNFSF13B Antibodies) promotes IL-10 (show IL10 Antibodies) production by CpG-activated B cells and enhances the regulatory role of B cells on T cells.
BCMA (show TNFRSF17 Antibodies) has other contributors for ligands binding except DxL motif. The affinity of BCMA (show TNFRSF17 Antibodies) for APRIL higher than for BAFF (show TNFSF13B Antibodies) may be caused by the segment outside of the conservative DxL motif. Moreover, the exposition of new binding modes of BCMA2 interacting with APRIL may establish the foundation of designing novel drugs in the future
ApoE-/-APRIL-Tg mice have increased oxLDL-specific serum IgM levels, potentially mediated via an increase in B1a lymphocytes
Results showed that chemokine (show CCL1 Antibodies)-mediated recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression.
This study showed that both BAFF (show TNFSF13B Antibodies) and APRIL levels were increased in CSF (show CSF2 Antibodies) of patients with anti-NMDAR (show GRIN1 Antibodies) encephalitis.
New molecular mechanisms of in vivo Multiple Myeloma (MM) growth and immunosuppression critically dependent on BCMA (show TNFRSF17 Antibodies) and APRIL in the Bone marrow microenvironment, further supporting targeting this prominent pathway in MM.
Urinary APRIL (uAPRIL) and BAFF (show TNFSF13B Antibodies) (uBAFF) levels were raised significantly in AN.
p40 (show LANCL1 Antibodies), a Lactobacillus rhamnosus-derived protein upregulates EGFR (show EGFR Antibodies)-dependent APRIL expression in intestinal epithelial cells, which may contribute to promoting IgA (show IgA Antibodies) production
this study identifies APRIL as a new target involved in B-cell activation (show BLNK Antibodies), in the maintenance of plasma cell survival and subsequent increased autoantibody production that sustains lupus development in mice
this is the first study to implicate the APRIL signal transduction pathway in the pathogenesis of nephrogenic IgA (show IgA Antibodies) production. Moreover, our findings identify APRIL as a potential target of therapy.
the elevated presence of APRIL and BLyS (show TNFSF13B Antibodies) in B cell-rich areas of chronically inflamed gingiva suggests that these cytokines may contribute to bone loss by promoting the survival and persistence of RANKL (show TNFSF11 Antibodies)-expressing B cells/plasma cells.
B cell activating factor (BAFF (show TNFSF13B Antibodies)) and a proliferation inducing ligand (APRIL) mediate CD40 (show CD40 Antibodies)-independent help by memory CD4 (show CD4 Antibodies) T cells in transplantations.
Heteromers consisting of one BAFF (show TNFSF13B Antibodies) and two APRIL bind to receptor TACI (show TNFRSF13B Antibodies), BCMA (show TNFRSF17 Antibodies) but not to BAFFR (show TNFRSF13C Antibodies).
Immunization of mice with a DNA vaccine encoding BAFF (show TNFSF13B Antibodies) or APRIL multitrimers, together with interleukin 12 and membrane-bound HIV-1 Env (show ERVW-1 Antibodies) gp140, induced neutralizing antibodies against tier 1 and tier 2 (vaccine strain) viruses.
APRIL selectively enhances axonal growth by activating ERK signaling and PI3-kinase/Akt/GSK-3beta signaling.
Data indicate that APRIL expression accelerates the onset of TCL1 (show TCL1A Antibodies)-driven leukemia formation mainly through TACI (show TNFRSF13B Antibodies) activation.
The ability of TACI (show TNFRSF13B Antibodies)-Fc to activate reverse signalling through BAFF (show TNFSF13B Antibodies) and APRIL, was investigated.
Although proliferation-inducing ligand TNFSF13/APRIL expression is dispensable for B cell development in the bone marrow, it is required for B cell development in gut (show GUSB Antibodies)-associated lymphoid tissue.
Cloning and expression analysis of a proliferation-inducing ligand (APRIL) provides the basis for investigation of its role in regulating rabbit B-lymphocyte (show AKAP17A Antibodies) development and immune responses.
The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF17/BCMA, a member of the TNF receptor family. This protein and its receptor are both found to be important for B cell development. In vitro experiments suggested that this protein may be able to induce apoptosis through its interaction with other TNF receptor family proteins such as TNFRSF6/FAS and TNFRSF14/HVEM. Alternative splicing results in multiple transcript variants. Some transcripts that skip the last exon of the upstream gene (TNFSF12) and continue into the second exon of this gene have been identified\; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13.
TNF- and APOL-related leukocyte expressed ligand 2
, a proliferation-inducing ligand
, tumor necrosis factor ligand superfamily member 13
, tumor necrosis factor-like protein ZTNF2
, tumor necrosis factor-related death ligand-1
, SLAN protein
, Acidic leucine-rich nuclear phosphoprotein 32 family member B
, TNF superfamily member 13
, A proliferation-inducing ligand
, tumor necrosis factor ligand superfamily member 13 isoform alpha proprotein
, tumor necrosis factor (ligand) superfamily, member 13
, tumor necrosis factor superfamily member 13
, proliferation-inducing ligand
, tumor necrosis factor ligand 7B